Lgi3 Antibody

What is LGI3 and why is it important for research?

LGI3 functions as a pleiotropic cytokine involved in regulating tumor necrosis factor-α (TNF-α) and adiponectin. Research has demonstrated LGI3's involvement in inflammatory responses and potential connections to various pathological conditions. Studies using knockout mouse models have shown that LGI3 regulates multiple cytokines and adipokines, suggesting its importance in inflammatory networks . Additionally, LGI3 is highly expressed in several cancer types including glioma, neuroblastoma, melanoma, colon, and breast cancer cells . Functional annotation clustering analyses indicate that LGI3 participates in various biological processes including hormonal responses, proliferation, wound healing, inflammatory processes, and apoptosis .

What molecular properties characterize the LGI3 protein?

LGI3 is a 548 amino acid protein with a calculated molecular weight of approximately 62 kDa, though it typically appears as a band between 55-62 kDa on Western blots . The protein contains leucine-rich repeat domains that contribute to its structural and functional properties. The amino acid sequence is relatively conserved across species, with specific regions such as amino acids 405-421 of rat LGI3 completely matching the corresponding human sequence . This conservation facilitates cross-species research applications and antibody development. In cellular contexts, LGI3 has been observed in the cytoplasm, plasma membranes, and nuclei of various cell types, including cultured astrocytes .

What types of LGI3 antibodies are available for research?

Research-grade LGI3 antibodies are available in various formats to accommodate different experimental needs:

Additionally, some antibodies are available with conjugates such as biotin, AbBy Fluor® 594, and AbBy Fluor® 350 for specialized applications .

What are the common applications for LGI3 antibodies?

LGI3 antibodies have been validated for multiple experimental applications:

• Western Blotting (WB): Detects LGI3 protein (55-62 kDa) in cell and tissue lysates from human, mouse, and rat samples .

• Immunohistochemistry (IHC): Visualizes LGI3 distribution in tissues, with positive reactivity confirmed in human lung and brain tissues .

• Immunofluorescence (IF)/Immunocytochemistry (ICC): Localizes LGI3 within cells, showing cytoplasmic, membrane, and nuclear distribution patterns .

• Enzyme-Linked Immunosorbent Assay (ELISA): Quantifies LGI3 levels in various biological samples .

• Flow Cytometry (FACS): Analyzes LGI3 expression at the cellular level .

These applications enable comprehensive investigation of LGI3 expression, localization, and function across different experimental models.

What cells and tissues are optimal for LGI3 antibody validation?

For antibody validation, certain cells and tissues have demonstrated reliable LGI3 expression:

These samples provide appropriate positive controls for validating antibody specificity and optimizing experimental conditions.

What are the recommended protocols for using LGI3 antibodies in Western Blotting?

For optimal Western Blotting results with LGI3 antibodies, follow these methodological guidelines:

• Sample preparation: Standard protein extraction methods from cells or tissues are suitable. LGI3 has been successfully detected in cell lines (HepG2, A549, SMMC-7721) and tissue samples (mouse lung, mouse liver) .

• Gel electrophoresis: Use 10-12% polyacrylamide gels for optimal resolution of LGI3 (55-62 kDa).

• Transfer and blocking: After transfer to PVDF or nitrocellulose membrane, block with 5% non-fat milk or BSA in TBST.

• Antibody incubation: Use LGI3 antibody at 1:500-1:2000 dilution in blocking buffer . Incubate overnight at 4°C for best results.

• Detection: After washing, apply appropriate HRP-conjugated secondary antibody and visualize using enhanced chemiluminescence.

• Controls: Use recombinant LGI3 protein as a positive control. If available, samples from LGI3 knockout models serve as excellent negative controls. Antibody specificity can be confirmed through peptide competition assays, where preabsorption with the specific antigen peptide should abolish immunoreactivity .

Expected result: LGI3 will appear as a band at approximately 55-62 kDa .

How can I optimize immunohistochemistry and immunofluorescence protocols for LGI3 detection?

Successful immunostaining for LGI3 requires careful optimization:

• Fixation: For cultured cells, 4% paraformaldehyde is suitable. For tissue sections, formalin fixation and paraffin embedding are compatible with LGI3 antibodies .

• Antigen retrieval: Critical for FFPE tissues. Recommended methods include TE buffer at pH 9.0 or citrate buffer at pH 6.0 .

• Blocking: Use serum corresponding to the host of the secondary antibody. For IHC with HRP-based detection, include a step to block endogenous peroxidase activity.

• Primary antibody: Use LGI3 antibody at 1:20-1:200 dilution . Optimize by testing multiple dilutions.

• Secondary antibody: For fluorescence, select secondary antibodies with appropriate fluorophores that match your microscopy setup. For colorimetric IHC, HRP-conjugated secondaries with DAB substrate work well.

• Controls: Include positive controls (human lung/brain tissue) and negative controls (primary antibody omission, peptide competition).

• For colocalization studies: When examining LGI3 alongside other proteins (e.g., Aβ), use primary antibodies from different host species and fluorophore-conjugated secondaries with distinct emission spectra .

• Imaging: For subcellular localization, confocal microscopy provides superior resolution. Studies have shown LGI3 localization in the cytoplasm, plasma membranes, and nuclei of cultured astrocytes .

How do I troubleshoot non-specific binding with LGI3 antibodies?

Address non-specific binding issues with these methodological approaches:

• Optimize antibody concentration: Excessive antibody can increase background. Test dilutions within recommended ranges (1:500-1:2000 for WB; 1:20-1:200 for IHC/IF) .

• Improve blocking: Extend blocking time or try alternative blocking agents (BSA, normal serum, commercial blockers).

• Increase washing steps: More thorough washing between antibody incubations can reduce background.

• Validate antibody specificity: Perform peptide competition assays. Preabsorption with the specific antigen peptide should abolish immunoreactivity, as demonstrated with the anti-TA142 LGI3 antibody .

• Optimize antigen retrieval: For IHC, test both recommended methods (TE buffer pH 9.0 and citrate buffer pH 6.0) .

• Consider antibody purification: For polyclonal antibodies with high background, affinity purification against the immunizing peptide may help, similar to the two-step chromatography method used for anti-TA142 antibody .

• Sample-specific adjustments: Reactivity can vary between sample types. Protocols that work for one tissue may require modification for others .

• Secondary antibody controls: Include controls omitting primary antibody to detect non-specific secondary antibody binding.

What is the optimal storage and handling of LGI3 antibodies?

Proper storage and handling are essential for maintaining antibody performance:

• Storage temperature: Store LGI3 antibodies at -20°C for long-term preservation. They remain stable for one year after shipment when stored properly .

• Buffer composition: Most commercial LGI3 antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps maintain stability .

• Aliquoting: While generally recommended to avoid freeze-thaw cycles, some product information indicates that aliquoting may be unnecessary for -20°C storage depending on the specific formulation .

• Working dilutions: Prepare fresh working dilutions on the day of the experiment.

• Handling precautions: Avoid repeated freeze-thaw cycles as they can lead to antibody degradation and reduced performance.

• Stabilizers: Some smaller antibody quantities (20μl) contain 0.1% BSA as a stabilizer .

• Shipping conditions: Most antibodies ship with ice packs and should be transferred to -20°C storage immediately upon receipt.

Following these guidelines will help maintain antibody quality and experimental reproducibility.

How does LGI3 interact with inflammatory pathways?

LGI3 functions as a pro-inflammatory mediator through multiple mechanisms:

• Inflammatory gene regulation: Treatment with LGI3 protein upregulates numerous inflammatory genes in multiple cell types:

  • In 3T3-L1 pre-adipocytes: Increases CD11c, CD68, IL-6, MCP-1, NOX-2, p67phox, and TNF-α

  • In 3T3-L1 adipocytes: Enhances CD68, IL-6, iNOS, MCP-1, NOX-2, p47phox, p67phox, and TNF-α

  • In RAW 264.7 macrophages: Increases CD11c, CD68, F4/80, iNOS, MCP-1, NOX-2, p22phox, p47phox, p67phox, and TNF-α

• Cytokine/adipokine network modulation: LGI3 knockout mice exhibit altered profiles:

  • Increased levels: Adiponectin, IGFBP-1, CRP, endocan, Pref-1, serpin E1, C5/C5a, M-CSF

  • Decreased levels: IGF-1, IGFBP-5, BLC, G-CSF, MCP-5, MIP-2, TIMP-1

These findings establish LGI3 as a key regulator within inflammatory networks, potentially contributing to inflammation-associated pathologies. The pro-inflammatory effects appear to be direct and involve multiple signaling pathways and inflammatory mediators.

What is known about LGI3's role in cancer research?

LGI3 shows significant connections to cancer through several mechanisms:

• Cancer-specific expression: LGI3 is expressed at high levels in glioma, neuroblastoma, melanoma, colon, and breast cancer cells . Among LGI family members, LGI3 is uniquely expressed at very high levels in gliomas, melanomas, and neuroblastoma cells .

• Oncogenic pathway involvement: Functional enrichment analysis reveals that LGI3-regulated gene products are associated with various cancers including prostate, melanoma, endometrial, and glioma cancers .

• Cytokine network regulation: LGI3 regulates TNF-α and adiponectin , both of which are recognized as risk factors and potential prognostic biomarkers in various cancer types .

• Biological process modulation: LGI3 affects processes relevant to cancer development including hormonal stimuli responses, proliferation, wounding and inflammatory responses, and apoptosis .

These findings suggest potential roles for LGI3 in cancer development, progression, or tumor microenvironment modulation. Further research is needed to fully elucidate whether LGI3 could serve as a biomarker or therapeutic target in specific cancer contexts.

How can I examine the colocalization of LGI3 with other proteins?

Investigating protein colocalization with LGI3 requires specialized techniques:

• Double immunostaining protocol:

  • Select primary antibodies from different host species (e.g., rabbit anti-LGI3 and mouse anti-target protein)

  • Use fluorophore-conjugated secondary antibodies with distinct emission spectra

  • Include appropriate controls (single-stained samples, negative controls)

• Imaging considerations:

  • Use confocal microscopy for superior optical sectioning and spatial resolution

  • Capture z-stacks to examine colocalization in three dimensions

  • Apply consistent acquisition parameters across all samples

• Colocalization analysis:

  • Calculate quantitative metrics (Pearson's correlation coefficient, Mander's overlap coefficient)

  • Use colocalization analysis software for objective assessment

• Example from research: Studies have successfully demonstrated colocalization between LGI3 and Aβ in cultured astrocytes:

  • "After 3 h of Aβ42 treatment, LGI3 and Aβ colocalized at plasma membranes"

  • Both proteins appeared "punctate and granular" at plasma membranes

  • "Internalized Aβ also colocalized with LGI3 in the cultured astrocytes"

  • When internalized, both appeared as "large granular matter"

This methodological approach can be adapted to study LGI3's interaction with other proteins of interest in various cellular contexts.

What molecular techniques are best for studying LGI3 gene expression changes?

Multiple complementary techniques provide comprehensive analysis of LGI3 expression:

• Semiquantitative RT-PCR:

  • Successfully used for LGI3 expression analysis

  • Requires specific primers designed by comparing known sequences using tBLASTn (used to compare human LGI3 AF467956 with rat LGI3 XM224337)

  • Provides basic assessment of expression levels

• Quantitative real-time PCR (qPCR):

  • Offers precise quantification of expression changes

  • Used to measure LGI3-induced alterations in inflammatory gene expression

  • Requires normalization to stable reference genes

• Western blotting:

  • Detects LGI3 protein (~60-kDa band) in various samples

  • Successfully demonstrated that "after 3 h of Aβ treatment, LGI3 protein expression increased significantly"

  • Requires densitometric quantification normalized to loading controls

• Functional expression studies:

  • Treatment with recombinant LGI3 protein reveals its regulatory effects on target genes

  • Useful for mechanistic investigations

• Protein arrays:

  • Analyzed cytokine and adipokine profiles in wild-type versus LGI3 knockout mice

  • Reveals broader effects on protein networks

Combining these approaches provides comprehensive insights into LGI3 expression changes at both mRNA and protein levels, along with functional consequences.

How can LGI3 knockout models be utilized in research?

LGI3 knockout models offer valuable research opportunities:

• Model characteristics:

  • Homozygous mice with LGI3 gene disruption are viable and fertile

  • Exhibit no gross abnormalities under normal growth conditions

  • Show increased levels of adiponectin in white adipose tissue (WAT) and plasma

• Altered inflammatory profiles:

  • Multiple cytokines and adipokines are increased or decreased in knockout mice

  • Protein arrays of WAT and plasma reveal specific molecular signatures

• Research applications:

  • Investigating LGI3's regulatory role in inflammatory networks

  • Examining consequences of LGI3 deficiency in disease models

  • Serving as negative controls for antibody validation

  • Studying compensatory mechanisms in the absence of LGI3

• Experimental approaches:

  • Protein arrays on tissue samples and plasma compared to wild-type controls

  • Challenging with inflammatory stimuli to reveal LGI3's role in acute responses

  • Tissue-specific analyses to identify differential effects across organs

  • Age-dependent studies to examine developmental or aging-related phenotypes

These models provide powerful tools for understanding LGI3's physiological and pathological roles through loss-of-function studies.

How do I quantify and analyze LGI3 expression changes?

Proper quantification of LGI3 expression requires methodological rigor:

• RNA-level quantification:

  • Use qPCR with appropriate reference gene normalization

  • Apply the 2^(-ΔΔCT) method to calculate fold changes

  • Include at least three biological replicates

  • Perform statistical analysis (t-test or ANOVA with post-hoc tests)

• Protein-level quantification:

  • For Western blots: Perform densitometric analysis of the ~60-kDa LGI3 band

  • Normalize to loading controls (β-actin, GAPDH)

  • Use software like ImageJ for quantification

  • Consider dynamic range limitations

• Time-course considerations:

  • LGI3 expression can change over time, as seen with Aβ treatment:

    • Significant increase after 3 hours

    • Return to baseline after 24 hours

  • Include appropriate time points to capture dynamic responses

• Statistical approaches:

  • For two-group comparisons: t-test (parametric) or Mann-Whitney (non-parametric)

  • For multiple groups: ANOVA with post-hoc tests (Tukey's, Bonferroni)

  • For time-course data: repeated measures ANOVA or mixed-effects models

  • Report significance levels consistently (e.g., *p<0.05)

• Data visualization:

  • Use bar graphs with error bars (SD or SEM) for expression comparisons

  • Include individual data points when possible to show distribution

  • For time-course data, line graphs with error bars show temporal patterns

Following these methodological guidelines ensures robust quantification and analysis of LGI3 expression changes.

How do I interpret contradictory results in LGI3 expression studies?

Several factors can contribute to discrepancies in LGI3 expression data:

• Antibody differences:

  • Different epitopes might be differentially accessible

  • Antibody specificity can vary (validate with peptide competition )

  • Cross-reactivity profiles differ between antibodies

• Model-specific responses:

  • Cell type variations: The search results show that Aβ treatment affected LGI3 expression in astrocytes but not in primary cerebral cortical cultures

  • Species differences (human vs. mouse vs. rat) may influence results

• Temporal dynamics:

  • LGI3 expression increased after 3 hours of Aβ treatment but returned to baseline after 24 hours

  • Sampling at different timepoints can yield contradictory results

• Methodological variations:

  • Sample preparation methods

  • Protein extraction protocols

  • Detection techniques and sensitivities

• Biological complexity:

  • LGI3 regulation may involve feedback mechanisms

  • Context-dependent effects (tissue environment, culture conditions)

  • Genetic background variations between models

When encountering contradictory results, systematically analyze these factors and consider whether the differences reflect genuine biological complexity rather than experimental artifacts. Direct comparison experiments with standardized protocols are often necessary to resolve discrepancies.

What controls are essential for validating LGI3 antibody specificity?

Comprehensive validation requires multiple controls:

• Positive tissue/cell controls:

  • Western blotting: HepG2 cells, A549 cells, SMMC-7721 cells, mouse lung/liver tissue

  • IHC: Human lung tissue, human brain tissue

  • IF/ICC: HepG2 cells, cultured astrocytes

• Negative controls:

  • LGI3 knockout samples (tissues from LGI3 knockout mice)

  • Primary antibody omission controls

  • Isotype controls (irrelevant antibody of same isotype)

• Peptide competition:

  • Preabsorption with specific antigen peptide should abolish immunoreactivity

  • "TA142 immunoreactivity was completely abolished by preabsorption with specific antigen peptide"

• Molecular weight verification:

  • Confirm detection of a band at the expected size (55-62 kDa)

  • Use recombinant LGI3 protein as size reference

• Multi-technique validation:

  • Consistent results across different methods (WB, IHC, IF)

  • Correlation between protein and mRNA detection

• Cross-validation:

  • Testing multiple antibodies targeting different epitopes

  • Comparing commercial antibodies from different sources

These complementary validation approaches ensure reliable and specific detection of LGI3, minimizing the risk of false positive or negative results.

What are the expected results when studying LGI3 in different pathological contexts?

LGI3 expression and function show context-specific patterns:

• Neurological conditions:

  • In Alzheimer's disease models: LGI3 is upregulated by Aβ treatment in astrocytes

  • After 3 hours of treatment, both Aβ40 and Aβ42 increased LGI3 expression, with Aβ42 causing greater effects

  • LGI3 colocalizes with Aβ at plasma membranes and in internalized granules

• Inflammatory conditions:

  • LGI3 functions as a pro-inflammatory mediator

  • Upregulates numerous inflammatory genes in pre-adipocytes, adipocytes, and macrophages

  • LGI3 knockout mice show altered inflammatory profiles

• Cancer contexts:

  • High expression in glioma, neuroblastoma, melanoma, colon, and breast cancer cells

  • Regulates factors (TNF-α, adiponectin) recognized as cancer risk indicators

  • Gene products regulated by LGI3 are associated with various cancer types

• Metabolic disorders:

  • Regulates adiponectin levels in adipose tissue and plasma

  • May participate in adipose tissue inflammation relevant to obesity and related conditions

These context-specific patterns suggest differential roles for LGI3 across pathological conditions, emphasizing the importance of examining its expression and function in disease-relevant experimental models.

How can I design experiments to study LGI3 function beyond expression analysis?

Beyond expression studies, functional investigations require specialized approaches:

• Gain-of-function studies:

  • Treatment with recombinant LGI3 protein (10 ng/ml used in published studies)

  • Examine effects on inflammatory gene expression in various cell types

  • Analyze downstream signaling pathways activated by LGI3

• Loss-of-function approaches:

  • Utilize LGI3 knockout mouse models

  • Employ siRNA or shRNA knockdown in cell culture systems

  • Apply CRISPR-Cas9 genome editing for targeted modifications

• Interaction studies:

  • Immunoprecipitation to identify protein binding partners

  • Proximity ligation assays to confirm in situ protein interactions

  • Double immunostaining to examine colocalization (as done with LGI3 and Aβ)

• Mechanistic investigations:

  • Pathway inhibitor studies to determine signaling mechanisms

  • Promoter analysis to identify transcriptional regulation

  • Structure-function analysis using deletion or point mutants

• Physiological relevance:

  • Challenge LGI3 knockout models with disease-relevant stimuli

  • Examine LGI3 expression in patient samples vs. controls

  • Correlate LGI3 levels with clinical parameters or outcomes

These complementary approaches provide comprehensive insights into LGI3's functional roles, moving beyond descriptive expression analysis toward mechanistic understanding.